计算机断层扫描纹理分析对接受程序性死亡受体1及程序性死亡配体1抑制剂治疗的转移性尿路上皮癌患者的预测作用
本研究纳入42例铂类治疗后接受PD-1/PD-L1抑制剂治疗的转移性尿路上皮癌患者,最终31例可评估。首次随访CT的均值和熵在无进展生存期<12个月的患者中更高(p=0.005和p=0.02)。基于首次随访CT均值和熵的预测模型识别无进展生存期<12个月患者的敏感度95%、特异度80%、准确率90%(AUC=0.963)。
要点
- 首次随访CT纹理参数均值与熵在无进展生存期<12个月患者中更高。
- 基于首次随访CT均值与熵的模型识别早期进展敏感度95%、特异度80%。
- CT纹理分析或有助于早期预测PD-1/PD-L1抑制剂治疗后的进展。
核心结论
- CT纹理分析可在开始PD-1/PD-L1抑制剂治疗后不久以较高准确率帮助预测早期进展。
研究设计与样本
- 研究纳入2013年至2018年接受PD-1/PD-L1抑制剂治疗的42例铂类治疗后转移性尿路上皮癌患者,最终31例纳入分析。
- 纳入标准包括RECIST 1.1可测量病灶且开始治疗后3个月内具有增强基线或首次随访CT。
- 排除随访<12个月且无进展的11例患者。
- 使用TexRAD软件以不同空间缩放因子(0,2-6)提取基线和首次随访CT可测量病灶的纹理特征。
主要发现
- 31例纳入患者中18例无进展生存期<12个月。
- 25次基线CT和29次首次随访CT符合纳入标准。
- 无进展生存期<12个月的患者首次随访CT的熵和均值更高(p=0.02和p=0.005)。
- 基于首次随访CT均值和熵的预测模型识别无进展生存期<12个月患者的敏感度95%、特异度80%、阳性预测值90%、阴性预测值89%、准确率90%(曲线下面积=0.963)。
临床怎么用
- 作者认为CT纹理分析可在PD-1/PD-L1抑制剂治疗早期帮助预测转移性尿路上皮癌患者的缓解持久性。
- 作者认为研究纹理分析与生存终点的相关性可能有助于验证纹理分析作为PD-1/PD-L1抑制剂治疗反应生物标志物。
局限性
- 局限性包括回顾性研究性质和样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reliable biomarkers to predict the response of metastatic urothelial cancer (mUC) to programmed death-1 and programmed death-ligand 1 (PD-1/PD-L1) inhibitors are being investigated. Texture analysis represents tumor heterogeneity and may serve as a predictor of response in mUC. OBJECTIVE: To assess the predictive ability of computed tomography (CT) texture analysis for progression-free survival (PFS) in patients with mUC treated with PD-1/PD-L1 inhibitors. DESIGN, SETTING, AND PARTICIPANTS: Forty-two postplatinum patients with mUC treated with PD-1/PD-L1 inhibitors from 2013 to 2018, including those with measurable disease per RECIST 1.1 who had contrast-enhanced baseline or first follow-up CT within 3mo after starting treatment, were included. PFS was calculated based on serial follow-up CT scans. Eleven patients with follow-up of <12mo without progression were excluded. Texture features of measurable lesions on baseline and first follow-up CT were extracted using commercially available software (TexRAD; Feedback Plc, Cambridge, UK) using different spatial scaling factors (0, 2-6). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Stepwise logistic regression analysis was conducted to identify patients with PFS <12mo, and performance was assessed using receiver operator characteristic curves. RESULTS AND LIMITATIONS: Of 31 included patients, 18 had PFS <12mo. Twenty-five baseline CT and 29 first follow-up CT scans met the inclusion criteria. In patients with PFS <12mo, entropy and mean were higher on first follow-up CT (p=0.02 and p=0.005, respectively). A predictive model including mean and entropy on first follow-up CT yielded 95% sensitivity, 80% specificity, 90% positive predictive value, 89% negative predictive value, and 90% accuracy (area under the curve=0.963) to identify patients with PFS <12mo. Limitations include retrospective nature and small sample size. CONCLUSIONS: CT texture analysis can help predict early progression with high accuracy soon after starting PD-1/PD-L1 inhibitors. Studies investigating the correlation of texture analysis with survival endpoints may help validate texture analysis as a biomarker of PD-1/PD-L1 inhibitors' treatment response. PATIENT SUMMARY: Computed tomography texture analysis can help predict durability of response in patients with metastatic urothelial cancer early during treatment with programmed death-1 and programmed death-ligand 1 (PD-1/PD-L1) inhibitors.
引用
- Alessandrino F, Gujrathi R, Nassar AH, et al. Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors. Eur Urol Oncol. 2019. PMID: 31412003. doi:10.1016/j.euo.2019.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。